<DOC>
	<DOCNO>NCT02472782</DOCNO>
	<brief_summary>This study aim investigate possible correlation parameter affect physician ' therapeutic choice patient ' overall adherence osteoporosis treatment . Secondary end-points include correlation parameter affect physician ' therapeutic choice patient ' quality life well evaluation whole osteoporosis treatment approach orthopedic surgeon Greece ( diagnostic mean , use diagnostic treatment guideline , methodology follow - ) .</brief_summary>
	<brief_title>Adherence Osteoporosis Treatment Physicians ' Perception Regarding Osteoporosis Medication</brief_title>
	<detailed_description>The study include 100 orthopedic surgeon private sector work private office . The selection group physicians resides fact orthopedic surgeon work private office hold 60 % osteoporosis prescription Greece . Each physician fill questionnaire regard parameter affect his/her choice osteoporosis treatment enter patient study . Following completion questionnaire every physician recruit 10 patient study eligible osteoanabolic treatment ( teriparatide ) accord standard medical practice Greek osteoporosis treatment guideline . Each patient receive teriparatide 24 month he/she fill Greek EQ5D questionnaire month : 0,12,24 early discontinuation . Adherence treatment evaluate time point well monthly telephone interview . Both adherence treatment possible alteration patient ' quality life ( evaluate EQ5D questionnaire ) study correlate parameter affect initial therapeutic decision physician</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<criteria>Female patient postmenopausal osteoporosis ( Tscore ≤2,5 SD skeletal site ) osteoporosis treatment ( except teriparatide ) least one year history ≥ lowenergy fracture last 10 year prior study . Male patient ≥ 50 year old idiopathic osteoporosis ( Tscore ≤2,5 SD skeletal site ) osteoporosis treatment ( except teriparatide ) least one year history ≥ lowenergy fracture last 10 year prior study . Male female patient steroidinduced osteoporosis ( Tscore ≤2,5 SD skeletal site ) osteoporosis treatment ( except teriparatide ) least one year history ≥ lowenergy fracture last 10 year prior study . Prior use teriparatide PTH ( 184 ) Hypersensitivity teriparatide regimen . Pregnancy lactation . Hypercalcamia . Renal deficiency ( eGFR &lt; 30 ml/min ) . Other bone metabolic disease ( include hyperparathyroidism Paget 's disease ) except primary osteoporosis steroid induce osteoporosis . Uninterpretable increase alkaline phosphatase ( ALP ) Prior skeletal radiotherapy . Skeletal malignancy bone metastasis</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>osteoporosis</keyword>
	<keyword>quality life</keyword>
	<keyword>adherence</keyword>
	<keyword>treatment</keyword>
</DOC>